| Literature DB >> 34262146 |
Eleonora Lai1, Pina Ziranu1, Dario Spanu1, Marco Dubois1, Andrea Pretta1,2,3, Simona Tolu1,2, Silvia Camera4, Nicole Liscia1,2, Stefano Mariani1, Mara Persano1, Marco Migliari1, Clelia Donisi1, Laura Demurtas1, Valeria Pusceddu1, Marco Puzzoni1, Mario Scartozzi5.
Abstract
Despite continued research, pancreatic ductal adenocarcinoma (PDAC) remains one of the main causes of cancer death. Interest is growing in the role of the tumour suppressors breast cancer 1 (BRCA1) and BRCA2-typically associated with breast and ovarian cancer-in the pathogenesis of PDAC. Indeed, both germline and sporadic mutations in BRCA1/2 have been found to play a role in the development of PDAC. However, data regarding BRCA1/2-mutant PDAC are lacking. In this review, we aim to outline the specific landscape of BRCA-mutant PDAC, focusing on heritability, clinical features, differences between BRCA1 and 2 mutations and between germline and sporadic alterations, as well as established therapeutic strategies and those that are still under evaluation.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34262146 PMCID： PMC8575931 DOI： 10.1038/s41416-021-01469-9
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 9.075